Navigation Links
Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
Date:11/6/2007

ORLANDO, Fla., Nov. 6 /PRNewswire/ --

What and When

Additional results from the clinical trial, CHICAGO (Carotid intima-media tHICkness in Atherosclerosis using pioGlitazOne), will be presented as an oral session at the American Heart Association Scientific Sessions 2007 being held November 4 through 7, 2007 in Orlando, Florida.

Results revealed that reduced progression of carotid intima-media thickness (CIMT), the thickness of the inner lining of a patient's carotid, with ACTOS was associated with increased HDL cholesterol and decreased insulin levels when compared to glimepiride. An increase in CIMT is an indicator of atherosclerosis, a condition that leads to reduced or blocked blood flow and is a surrogate marker for the risk of heart attack and stroke.

CHICAGO is the largest and longest study to examine the effects of ACTOS on measures of the atherosclerotic disease process in patients with type 2 diabetes. The randomized, double-blind, controlled study enrolled 462 patients with type 2 diabetes. Patients were treated with a 15 to 45 mg dose of ACTOS or 1 to 4 mg dose of glimepiride for 72 weeks with evaluation after 6 months. The results from the CHICAGO study demonstrated significant improvements on cardiovascular risk markers beyond glycemic control with ACTOS.

The CHICAGO trial adds to the already substantial body of evidence regarding cardiovascular data that has been developed over several years of research on ACTOS.

Oral presentation on November 6, 2007 from

9:15 to 9:30 a.m. Eastern Standard Time

About ACTOS

ACTOS works by directly targeting insulin resistance, a condition in which the body does not efficiently use the insulin it produces to control blood glucose levels. ACTOS, a prescription medication, is taken once daily as an adjunct to diet and exercise, and is approved for use for type 2 diabetes as monotherapy to lower blood glucose and in combination therapy with insulin, sulfonylureas
'/>"/>

SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... -- Landauer, Inc. (NYSE: LDR ), a recognized leader ... medical physics services and high quality medical consumable accessories, ... fiscal third quarter 2015 after the market close on ... will also host a conference call for investors on ... (10:00 a.m. Eastern Time). Investors may access the live ...
(Date:8/3/2015)... 3, 2015 AcelRx Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapies for the treatment ... reported financial results for the three and six months ... , On July 23, 2015, the Committee for ... opinion for Zalviso™ for the management of acute moderate-to-severe ...
(Date:8/3/2015)... , Aug. 3, 2015  LEO Pharma supports ... Administration (FDA) to include psoriasis as one of eight ... Development Initiative i .  Psoriasis is an autoimmune disease ... subsequent comorbidities, affecting 7.5 million people in the US ... Pharma,s ongoing commitment to supporting patients living with psoriasis, ...
Breaking Medicine Technology:Landauer, Inc. Announces Date And Time For Announcement Of Fiscal Third Quarter 2015 Results And Conference Call 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 3AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 4AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 5AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 6AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 7AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 8AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 9AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 10LEO Pharma Supports the FDA's Selection of Psoriasis as a Priority Disease 2LEO Pharma Supports the FDA's Selection of Psoriasis as a Priority Disease 3
... Inc.,(Nasdaq: ITMN ) today announced that it ... pirfenidone in idiopathic pulmonary fibrosis (IPF) prior,to market open ... conference,call and webcast, with accompanying slide presentation, to discuss ... a.m. PST) on Tuesday,February 3. , ...
... led by Laurie Ozelius, Ph.D. at Mount Sinai School ... development of primary torsion dystonia, also known as DYT6 ... Research Foundation (DMRF), Dr. Ozelius and her colleagues have ... dystonia in Amish-Mennonite families, as well as in other ...
Cached Medicine Technology:InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3 2Genetic Research Leads to New Discovery in Understanding Rare Neurological Disorder 2
(Date:8/3/2015)... ... August 03, 2015 , ... sweetFrog Enterprises, LLC. is pleased ... the 20th sweetFrog store operating in the Lone Star State. The premium frozen yogurt ... in 2014. , The store, located at 2916 US-75, Sherman, TX 38652, will have ...
(Date:8/3/2015)... ... 03, 2015 , ... As reported in a July ... “Atlanta Plastic” is getting attention for moving outside traditional ethnic stereotypes when it ... cast of doctors and patients. Beverly Hills based plastic surgeon Payam Jarrah-Nejad, M.D., ...
(Date:8/3/2015)... NJ (PRWEB) , ... August 03, 2015 , ... ... a finalist in 2015 MarketingProfs Bright Bulb B2B Awards. , The MarketingProfs Bright ... and for B2B brands. BESLER Consulting's campaign for the launch of their Readmissions ...
(Date:8/3/2015)... Somerset, N.J. (PRWEB) , ... August 03, 2015 ... ... advanced delivery technologies and development solutions for drugs, biologics and consumer health products, ... Administration has accepted for review OPKO’s New Drug Application for a new treatment ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... The art ... experience. Learning from her grandmother’s side at a young age, Nasreen Zereshki was extremely ... has decided to share her cookbook Recipes from My Persian Kitchen with the world. ...
Breaking Medicine News(10 mins):Health News:sweetFrog Reopens Texas Store Today 2Health News:Article on Lifetime’s New “Atlanta Plastic” Reality Series Underlines the Diversity of Today’s Plastic Surgery Patients, Says Plastic Surgeon Dr. J 2Health News:Article on Lifetime’s New “Atlanta Plastic” Reality Series Underlines the Diversity of Today’s Plastic Surgery Patients, Says Plastic Surgeon Dr. J 3Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Persian Cuisine: Colorful and Extremely Healthy 2
... to extend their reach beyond the youth segments as far as ... For the aging population in Japan has taken to "Brain Train" ... Nintendo has sold 3.3 million of its "Brain Training for Adults" ... out to those who were not interested in video games ... ...
... People plan various phases of their life like education, marriage, ... do not plan for the most important thing - death. ... University of New Mexico's Health Sciences Center wants people to ... ,"We're all going to die. But we do not address ...
... (KSHV) and certain forms of lymphoma has been ... ,Researchers at the National Institute of Allergy ... human cell surface molecule involved in infection by ... Kaposi's sarcoma and certain forms of lymphoma. Kaposi's ...
... sporting sunglasses, don’t be surprised. They don't mean to be ... their looks! //Sunglasses have always afforded creative utility benefits and ... use. There is one more out of the hat use ... who have revealed that sunglasses can help reduce jet lag. ...
... culprit behind childhood obesity is that the amount of junk ... of hours they spend// watching television. Researchers analyzed the dietary ... countries. , It was found that consumption of ... in front of the idiot box. Researchers at the universities ...
... which is a male-dominated Muslim society, five women undergo sex ... are expected to fully cover themselves in public and ban ... relative. ,Hence five Saudi women took a sex ... developed a psychologic complex. ,Al Watan newspaper quoted ...
Cached Medicine News:Health News:Plan for Death, Health Center Advises People 2Health News:Virus Causing Kaposi's Sarcoma Discovered 2Health News:Virus Causing Kaposi's Sarcoma Discovered 3Health News:TV Viewing Increases Intake of Junk Food 2
... low osmolar, nonionic, contrast media agent ... inert when injected intra-arterially. Each milliliter ... ioversol, 3.6 mg of tromethamine as ... edetate calcium disodium as a stabilizer. ...
... OMNIPAQUE is an X-ray ... adults and children for: angiography, ... and computed tomography of the ... Arthrography, endoscopic retrograde cholangio (pancreato) ...
... IMAGOPAQUE is a non-ionic monomeric contrast medium ... adults and children. After a decade of ... million examinations, IMAGOPAQUE has proven to be ... in hundreds of radiology departments.Results from large ...
... The only MR contrast agent FDA-approved for ... a gadolinium based, IV contrast media for ... liver. OptiMARK has convenient packaging options ... packaged for efficient, problem-free delivery. You can ...
Medicine Products: